1. Home
  2. SKYE vs PSTL Comparison

SKYE vs PSTL Comparison

Compare SKYE & PSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKYE
  • PSTL
  • Stock Information
  • Founded
  • SKYE 2012
  • PSTL N/A
  • Country
  • SKYE United States
  • PSTL United States
  • Employees
  • SKYE N/A
  • PSTL N/A
  • Industry
  • SKYE Biotechnology: Pharmaceutical Preparations
  • PSTL Real Estate Investment Trusts
  • Sector
  • SKYE Health Care
  • PSTL Real Estate
  • Exchange
  • SKYE Nasdaq
  • PSTL Nasdaq
  • Market Cap
  • SKYE 294.2M
  • PSTL 302.7M
  • IPO Year
  • SKYE N/A
  • PSTL 2019
  • Fundamental
  • Price
  • SKYE $6.49
  • PSTL $14.08
  • Analyst Decision
  • SKYE Strong Buy
  • PSTL Strong Buy
  • Analyst Count
  • SKYE 4
  • PSTL 3
  • Target Price
  • SKYE $19.25
  • PSTL $16.17
  • AVG Volume (30 Days)
  • SKYE 428.5K
  • PSTL 131.3K
  • Earning Date
  • SKYE 01-01-0001
  • PSTL 08-06-2024
  • Dividend Yield
  • SKYE N/A
  • PSTL 6.84%
  • EPS Growth
  • SKYE N/A
  • PSTL N/A
  • EPS
  • SKYE N/A
  • PSTL 0.10
  • Revenue
  • SKYE N/A
  • PSTL $65,851,000.00
  • Revenue This Year
  • SKYE N/A
  • PSTL $13.72
  • Revenue Next Year
  • SKYE N/A
  • PSTL $14.27
  • P/E Ratio
  • SKYE N/A
  • PSTL $140.30
  • Revenue Growth
  • SKYE N/A
  • PSTL 16.45
  • 52 Week Low
  • SKYE $1.44
  • PSTL $12.98
  • 52 Week High
  • SKYE $19.41
  • PSTL $15.70
  • Technical
  • Relative Strength Index (RSI)
  • SKYE 38.55
  • PSTL 71.19
  • Support Level
  • SKYE $5.48
  • PSTL $13.48
  • Resistance Level
  • SKYE $6.93
  • PSTL $13.71
  • Average True Range (ATR)
  • SKYE 1.01
  • PSTL 0.17
  • MACD
  • SKYE -0.01
  • PSTL 0.11
  • Stochastic Oscillator
  • SKYE 46.71
  • PSTL 95.72

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About PSTL Postal Realty Trust Inc.

Postal Realty Trust Inc is an internally managed real estate corporation that owns and manages properties leased to the United States Postal Service, or the USPS. Its objective is to create stockholder value by generating risk-adjusted returns through expanding its portfolio of owned and managed postal properties leased to the USPS. The majority of the revenue is generated from the rental income received.

Share on Social Networks: